Shares of Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY – Get Free Report) traded down 2.5% during trading on Friday . The stock traded as low as $5.02 and last traded at $5.17. 32,115 shares changed hands during mid-day trading, an increase of 1% from the average session volume of 31,851 shares. The stock had previously closed at $5.30.
Ono Pharmaceutical Stock Performance
The stock’s 50 day simple moving average is $4.99 and its two-hundred day simple moving average is $5.02.
Ono Pharmaceutical Company Profile
Ono Pharmaceutical Co, Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and marketing of prescription drugs and diagnostics. Headquartered in Osaka, the company traces its origins to the early 18th century and has grown into a global specialty‐pharmaceutical firm. Its product portfolio spans oncology, immunology, allergy and inflammatory diseases, with a notable focus on novel immunotherapies.
In oncology, Ono Pharmaceutical is best known for co‐developing and commercializing nivolumab (Opdivo), an anti–PD‐1 immune checkpoint inhibitor developed in partnership with Bristol‐Myers Squibb.
Featured Stories
- Five stocks we like better than Ono Pharmaceutical
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
